BioLineRx (BLRX) Stock
BioLineRx Chart
Company Profile
Price: $3.05
Market Cap: $11.35M
Exchange: NASDAQ
CEO: Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Sector: Healthcare
Industry: Biotechnology
Employees: 79
Headquarters: Hevel Modi'in, None
Website: BioLineRx
Business Summary
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BioLineRx News
BioLineRx Issues Letter to Shareholders
- Company outlines strategic long-term vision and financial outlook - TEL AVIV, Israel , Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today issued the following letter to shareholders.
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
TEL AVIV, Israel , Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 15 ordinary shares per ADS to 600 ordinary shares per ADS.
BioLineRx Announces $10 Million Registered Direct Offering
TEL AVIV, Israel , Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) and accompanying warrants to purchase up to an aggregate of 50,000,000 ADSs, at a purchase price of $0.20 per ADS (or per ADS equivalent) and accompanying warrant in a registered direct offering.
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Mali Zeevi - CFO Conference Call Participants Joe Pantginis - HC Wainwright Justin Walsh - Jones Trading John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC – – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Trans actions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will provide further corporate updates on its Q3 results conference call, which is scheduled for November 25 at 8:30 am ET – TEL AVIV, Israel , Nov. 21, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
- Findings suggest motixafortide alone, and in combination with natalizumab, could support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle - - Data from proof-of-concept study shows that motixafortide was safe and well tolerated - - Oral presentation at ASH 2024 on Saturday, December 7, 2024 in San Diego, California - TEL AVIV, Israel and WALTHAM, Mass. , Nov. 5, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass. , Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host conference call today, August 15, at 8:30 am EDT - TEL AVIV, Israel , Aug. 15, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the second quarter ended June 30, 2024, and provided recent corporate and portfolio updates.
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital More modest sums of capital and a combination of risk and luck We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025.
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites - - New trial to expand ongoing clinical research of motixafortide for mobilization of HSCs in patients with SCD - TEL AVIV, Israel , May 30, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a multi-center Phase 1 clinical trial sponsored by St. Jude Children's Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).
BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2024 Earnings Call Transcript May 28, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Steady growth in APHEXDA ® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal of ~35% by end of Q2 - - Announced new data in abstract accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on pilot phase of ongoing Phase 2b pancreatic cancer clinical trial collaboration with Columbia University - - Collaboration partner Gloria Biosciences' motixafortide HSC mobilization bridging study IND was filed and approved by the Center for Drug Evaluation of the National Medical Products Administration in China. Anticipate clinical trial initiation 2H 2024 - - Completed debt and equity financing totaling $26 million to support U.S. commercialization of APHEXDA and advance lifecycle expansion activities - - Management to host conference call today, May 28, at 8:30 am EDT - TEL AVIV, Israel , May 28, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated 7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control Poster Presentation on Saturday, June 1, 2024 in Chicago, Illinois TEL AVIV, Israel , May 24, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that an abstract including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial was accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel , May 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a notification letter from the Nasdaq Stock Market LLC ("Nasdaq").
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
- Presentation Today, Monday, May 6, 2024 in Atlanta, Georgia - TEL AVIV, Israel , May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – The Professional Society for Health Economics and Outcomes Research – 2024 conference, taking place May 5-8, 2024, in Atlanta, Georgia.
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
TEL AVIV, Israel , April 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA (motixafortide) in patients with multiple myeloma.
BioLineRx Announces $6 Million Registered Direct Offering
TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of $0.80 per ADS and accompanying warrant.
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on formulary approvals at targeted major transplant centers; r eceived Healthcare Common Procedure Coding System (HCPCS) J-Code to facilitate Medicare reimbursement - - Announced first patient dosed in randomized Phase 2b clinical trial evaluating motixafortide in first-line pancreatic cancer - - Continued to support partner Gloria Biosciences in plans to execute pivotal bridging study of motixafortide in stem cell mobilization and Phase 2b randomized study in first-line pancreatic cancer in China - - Management to host conference call today, March 26, at 8:30 am EDT - TEL AVIV, Israel , March 26, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its financial results for the year ended December 31, 2023, and provided recent corporate and portfolio updates.
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
- Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - - Gulam Manji, MD, PhD, of Columbia University to present encore pilot phase data at the Immuno-Oncology (IO) 360° Summit on February 29 - TEL AVIV, Israel , Feb. 28, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and standard of care chemotherapies gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Results include pharmacokinetic and pharmacodynamic data, and post-hoc subgroup analyses of the Phase 3 GENESIS trial Presentations on Thursday, February 22, 2024 in San Antonio, Texas TEL AVIV, Israel , Feb. 16, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new post-hoc subgroup analyses and pharmacodynamic data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), taking place February 21-24, 2024, in San Antonio, Texas.
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
- Proof-of-concept study is initial step toward goal of identifying more efficient CD34+ HSC mobilization regimen for patients with sickle cell disease choosing gene therapy - TEL AVIV, Israel , Dec. 21, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD).
BioLineRx: Still A Buy, With Some Questions
BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination with other treatments for pancreatic cancer. Financially, BioLineRx has a limited amount of cash on hand but has secured a licensing deal that provides additional funds.
BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges
BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patients. BioLineRx's low cash reserves and need for additional financing pose risks, but its valuation appears relatively conservative.
BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Conference Call Participants Joe Pantginis - H.C.
BioLineRx Earnings
This section highlights BioLineRx's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2024 | 2024-11-25 | $-0.05 | $-2.80 |
| Read Transcript | Q2 | 2024 | 2024-08-15 | $-0.14 | $0.40 |
| Read Transcript | Q1 | 2024 | 2024-05-28 | $-0.29 | $-0.01 |
| Read Transcript | Q4 | 2023 | 2024-03-26 | $-0.22 | $-0.15 |
| Read Transcript | Q3 | 2023 | 2023-11-20 | $-7.20 | $-12.00 |
| Read Transcript | Q2 | 2023 | 2023-08-30 | $-6.40 | $-12.00 |
| Read Transcript | Q1 | 2023 | 2023-05-24 | $-5.60 | $-6.00 |
Financial Statements
Access annual & quarterly financial statements for BioLineRx, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $4.80M | $- | $- | $- | $- |
| Cost of Revenue | $3.69M | $654.00K | $702.00K | $934.00K | $940.00K |
| Gross Profit | $1.11M | $-654.00K | $-702.00K | $-934.00K | $-940.00K |
| Gross Profit Ratio | 23.10% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $12.52M | $17.63M | $19.47M | $18.17M | $23.44M |
| General and Administrative Expenses | $16.64M | $5.07M | $4.27M | $3.84M | $3.74M |
| Selling and Marketing Expenses | $14.59M | $6.46M | $1.00M | $840.00K | $857.00K |
| Selling General and Administrative Expenses | $31.23M | $11.53M | $5.27M | $4.68M | $4.59M |
| Other Expenses | $7.05M | $5.67M | $42.00K | $70.00K | $78.00K |
| Operating Expenses | $50.80M | $29.16M | $24.78M | $22.93M | $28.11M |
| Cost and Expenses | $54.49M | $29.16M | $24.78M | $22.93M | $28.11M |
| Interest Income | $2.01M | $694.00K | $559.00K | $236.00K | $777.00K |
| Interest Expense | $2.17M | $2.16M | $984.00K | $1.47M | $1.83M |
| Depreciation and Amortization | $1.38M | $654.00K | $702.00K | $934.00K | $940.00K |
| EBITDA | $-57.06M | $-28.50M | $-25.35M | $-21.99M | $-27.17M |
| EBITDA Ratio | -1188.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-49.69M | $-29.16M | $-24.78M | $-22.93M | $-28.11M |
| Operating Income Ratio | -1035.29% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-10.92M | $4.21M | $-2.28M | $-7.09M | $2.67M |
| Income Before Tax | $-60.61M | $-24.95M | $-27.05M | $-30.02M | $-25.45M |
| Income Before Tax Ratio | -1262.79% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $1.00K | $-6.08M | $1.09M | $911.00K | $1.36M |
| Net Income | $-60.61M | $-18.87M | $-28.14M | $-30.93M | $-26.81M |
| Net Income Ratio | -1262.79% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.06 | $-0.02 | $-0.04 | $-0.12 | $-0.18 |
| EPS Diluted | $-0.06 | $-0.02 | $-0.04 | $-0.12 | $-0.18 |
| Weighted Average Shares Outstanding | 963.37M | 773.96M | 662.93M | 252.84M | 146.41M |
| Weighted Average Shares Outstanding Diluted | 963.37M | 773.96M | 662.93M | 252.84M | 146.41M |
| SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.94M | $5.39M | $6.86M | $4.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $822.00K | $897.00K | $1.46M | $3.69M | $221.00K | $198.00K | $259.00K | $187.00K | $153.00K | $141.00K | $173.00K | $174.00K | $167.00K | $180.00K | $182.00K | $- | $- | $- | $- | $- |
| Gross Profit | $4.12M | $4.50M | $5.40M | $1.11M | $-221.00K | $-198.00K | $-259.00K | $-187.00K | $-153.00K | $-141.00K | $-173.00K | $-174.00K | $-167.00K | $-180.00K | $-182.00K | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 83.40% | 83.40% | 78.80% | 23.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $2.56M | $2.23M | $2.49M | $3.10M | $2.73M | $3.01M | $3.68M | $3.43M | $4.37M | $5.39M | $4.43M | $5.13M | $4.92M | $5.14M | $4.28M | $4.63M | $3.48M | $4.64M | $5.42M | $8.19M |
| General and Administrative Expenses | $1.39M | $1.63M | $1.39M | $12.54M | $1.50M | $1.30M | $1.30M | $1.58M | $1.39M | $1.05M | $1.01M | $1.16M | $1.05M | $1.04M | $1.02M | $1.00M | $856.00K | $744.00K | $1.24M | $975.00K |
| Selling and Marketing Expenses | $5.55M | $6.42M | $6.34M | $-3.02M | $8.13M | $5.60M | $3.87M | $3.35M | $1.32M | $1.16M | $637.00K | $272.00K | $247.00K | $330.00K | $154.00K | $174.00K | $309.00K | $182.00K | $175.00K | $174.00K |
| Selling General and Administrative Expenses | $6.94M | $8.04M | $7.73M | $9.87M | $9.63M | $6.91M | $5.17M | $4.93M | $2.71M | $2.21M | $1.64M | $1.43M | $1.29M | $1.37M | $1.17M | $1.18M | $1.17M | $926.00K | $1.42M | $1.15M |
| Other Expenses | $- | $- | $4.49M | $14.03M | $-3.14M | $-7.73M | $-2.92M | $39.00K | $389.00K | $458.00K | $1.27M | $42.00K | $710.00K | $-217.00K | $-4.56M | $-479.00K | $294.00K | $-843.00K | $469.00K | $-4.45M |
| Operating Expenses | $9.51M | $10.27M | $10.22M | $12.97M | $12.36M | $9.91M | $8.86M | $8.40M | $7.08M | $7.60M | $6.08M | $6.60M | $6.22M | $6.51M | $5.45M | $5.87M | $4.65M | $5.57M | $6.84M | $9.41M |
| Cost and Expenses | $10.33M | $11.17M | $11.68M | $16.66M | $12.36M | $9.91M | $8.86M | $8.40M | $7.08M | $7.60M | $6.08M | $6.60M | $6.22M | $6.51M | $5.45M | $5.87M | $4.65M | $5.57M | $6.84M | $9.41M |
| Interest Income | $434.00K | $535.00K | $565.00K | $1.68M | $312.00K | $440.00K | $537.00K | $438.00K | $109.00K | $80.00K | $67.00K | $260.00K | $52.00K | $130.00K | $117.00K | $22.00K | $39.00K | $35.00K | $140.00K | $149.00K |
| Interest Expense | $1.62M | $2.08M | $929.00K | $- | $837.00K | $1.34M | $927.00K | $954.00K | $267.00K | $379.00K | $186.00K | $182.00K | $261.00K | $242.00K | $299.00K | $358.00K | $302.00K | $396.00K | $414.00K | $345.00K |
| Depreciation and Amortization | $840.00K | $727.00K | $646.00K | $706.00K | $221.00K | $198.00K | $259.00K | $187.00K | $153.00K | $141.00K | $173.00K | $174.00K | $167.00K | $180.00K | $182.00K | $197.00K | $204.00K | $212.00K | $321.00K | $273.00K |
| EBITDA | $-3.36M | $3.30M | $879.00K | $-13.18M | $-14.96M | $-17.01M | $-10.98M | $-4.22M | $-6.43M | $-6.92M | $-4.57M | $-3.93M | $-5.29M | $-6.42M | $-9.71M | $-11.27M | $-4.11M | $-6.16M | $-5.91M | $-9.29M |
| EBITDA Ratio | -67.91% | 61.12% | 16.48% | -232.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-5.39M | $-5.77M | $-4.82M | $-11.86M | $-12.36M | $-9.91M | $-8.86M | $-8.40M | $-7.08M | $-7.60M | $-6.08M | $-6.60M | $-6.22M | $-6.51M | $-5.45M | $-5.87M | $-4.65M | $-5.57M | $-6.84M | $-9.41M |
| Operating Income Ratio | -108.98% | -107.05% | -70.34% | -247.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-435.00K | $6.26M | $4.13M | $-2.02M | $-3.67M | $-8.63M | $-3.31M | $2.67M | $231.00K | $159.00K | $1.15M | $2.29M | $501.00K | $-329.00K | $-4.74M | $-6.12M | $31.00K | $-1.20M | $195.00K | $-455.00K |
| Income Before Tax | $-5.82M | $484.00K | $-696.00K | $-13.88M | $-16.02M | $-18.55M | $-12.16M | $-5.73M | $-6.85M | $-7.44M | $-4.93M | $-4.30M | $-5.72M | $-6.84M | $-10.19M | $-11.99M | $-4.62M | $-6.77M | $-6.64M | $-9.87M |
| Income Before Tax Ratio | -117.78% | 8.97% | -10.15% | -289.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $5.42M | $662.19K | $-2.30M | $-6.40M | $3.31M | $-2.67M | $-231.00K | $-159.00K | $-1.15M | $-2.29M | $-501.00K | $329.00K | $4.74M | $6.12M | $-31.00K | $1.20M | $-195.00K | $455.00K |
| Net Income | $-5.82M | $484.00K | $-696.00K | $-13.88M | $-16.02M | $-18.55M | $-15.47M | $-3.06M | $-6.62M | $-7.28M | $-3.78M | $-2.01M | $-5.72M | $-6.84M | $-10.19M | $-11.99M | $-4.62M | $-6.77M | $-6.64M | $-9.87M |
| Net Income Ratio | -117.78% | 8.97% | -10.15% | -289.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $0.00 | $0.00 | $0.00 | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $0.00 | $-0.01 | $-0.01 | $-0.01 | $0.00 | $-0.01 | $-0.01 | $-0.02 | $-0.04 | $-0.02 | $-0.03 | $-0.04 | $-0.07 |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $0.00 | $-0.01 | $-0.01 | $-0.01 | $0.00 | $-0.01 | $-0.01 | $-0.02 | $-0.04 | $-0.02 | $-0.03 | $-0.04 | $-0.07 |
| Weighted Average Shares Outstanding | 1.20B | 1.20B | 1.09B | 1.09B | 929.06M | 922.96M | 922.96M | 922.96M | 740.77M | 715.37M | 715.16M | 708.47M | 708.47M | 669.14M | 559.54M | 296.51M | 296.51M | 220.32M | 176.45M | 148.92M |
| Weighted Average Shares Outstanding Diluted | 1.20B | 1.20B | 1.09B | 1.09B | 929.06M | 922.96M | 922.96M | 922.96M | 740.77M | 715.37M | 715.16M | 708.47M | 708.47M | 669.14M | 559.54M | 296.51M | 296.51M | 220.32M | 176.45M | 148.92M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $4.25M | $10.59M | $12.99M | $16.83M | $5.30M |
| Short Term Investments | $38.74M | $40.49M | $44.15M | $5.76M | $22.19M |
| Cash and Short Term Investments | $42.99M | $51.08M | $57.13M | $22.59M | $27.49M |
| Net Receivables | $708.00K | $721.00K | $142.00K | $141.00K | $613.00K |
| Inventory | $1.95M | $-41.22M | $- | $- | $- |
| Other Current Assets | $1.53M | $198.00K | $127.00K | $152.00K | $108.00K |
| Total Current Assets | $47.18M | $52.00M | $57.40M | $22.88M | $28.21M |
| Property Plant Equipment Net | $1.89M | $2.50M | $2.28M | $2.70M | $3.47M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $14.85M | $21.89M | $21.70M | $21.71M | $21.89M |
| Goodwill and Intangible Assets | $14.85M | $21.89M | $21.70M | $21.71M | $21.89M |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $- | $- |
| Total Non-Current Assets | $16.74M | $24.38M | $23.99M | $24.41M | $25.36M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $63.92M | $76.38M | $81.39M | $47.29M | $53.57M |
| Account Payables | $10.87M | $6.97M | $5.57M | $5.92M | $7.79M |
| Short Term Debt | $3.67M | $2.40M | $2.92M | $3.28M | $2.89M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $12.96M | $- | $- | $- | $1.27M |
| Other Current Liabilities | $3.35M | $1.32M | $1.23M | $1.44M | $1.28M |
| Total Current Liabilities | $30.85M | $10.68M | $9.72M | $10.64M | $11.97M |
| Long Term Debt | $7.92M | $10.36M | $1.73M | $4.40M | $7.56M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $11.93M | $4.51M | $1.86M | $10.22M | $658.00K |
| Total Non-Current Liabilities | $19.85M | $14.86M | $3.58M | $14.62M | $8.22M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $50.70M | $25.54M | $13.30M | $25.26M | $20.19M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $31.36M | $27.10M | $21.07M | $9.87M | $4.69M |
| Retained Earnings | $-390.61M | $-329.99M | $-305.04M | $-277.99M | $-247.97M |
| Accumulated Other Comprehensive Income Loss | $16.99M | $13.35M | $11.74M | $10.91M | $10.72M |
| Other Total Stockholders Equity | $355.48M | $338.98M | $339.35M | $279.24M | $265.94M |
| Total Stockholders Equity | $13.22M | $50.84M | $68.09M | $22.03M | $33.38M |
| Total Equity | $13.22M | $50.84M | $68.09M | $22.03M | $33.38M |
| Total Liabilities and Stockholders Equity | $63.92M | $76.38M | $81.39M | $47.29M | $53.57M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $63.92M | $76.38M | $81.39M | $47.29M | $53.57M |
| Total Investments | $38.74M | $40.49M | $44.15M | $5.76M | $22.19M |
| Total Debt | $11.59M | $12.32M | $4.65M | $7.68M | $10.46M |
| Net Debt | $7.34M | $1.74M | $-8.34M | $-9.15M | $5.16M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $8.84M | $9.62M | $5.99M | $4.25M | $7.73M | $10.10M | $9.07M | $10.59M | $13.11M | $14.00M | $11.45M | $12.99M | $14.08M | $17.48M | $16.05M | $16.83M | $6.55M | $5.52M | $5.07M | $5.30M |
| Short Term Investments | $20.34M | $30.44M | $22.18M | $38.74M | $18.24M | $22.71M | $34.22M | $40.49M | $44.16M | $29.15M | $39.14M | $44.15M | $48.13M | $48.08M | $42.04M | $5.76M | $14.28M | $21.78M | $16.11M | $22.19M |
| Cash and Short Term Investments | $29.17M | $40.06M | $28.17M | $42.99M | $25.97M | $32.81M | $43.29M | $51.08M | $57.26M | $43.15M | $50.59M | $57.13M | $62.20M | $65.57M | $58.08M | $22.59M | $20.83M | $27.30M | $21.18M | $27.49M |
| Net Receivables | $3.96M | $3.83M | $3.34M | $708.00K | $315.00K | $128.00K | $302.00K | $721.00K | $143.00K | $240.00K | $190.00K | $142.00K | $192.00K | $668.00K | $190.00K | $141.00K | $327.00K | $441.00K | $682.00K | $613.00K |
| Inventory | $3.54M | $3.63M | $2.89M | $1.95M | $1.35M | $- | $- | $-41.22M | $- | $- | $- | $- | $- | $- | $- | $-141.00K | $-327.00K | $-441.00K | $-682.00K | $-613.00K |
| Other Current Assets | $1.17M | $1.58M | $1.29M | $1.53M | $1.17M | $1.75M | $738.00K | $198.00K | $537.00K | $717.00K | $161.00K | $127.00K | $449.00K | $837.00K | $1.08M | $152.00K | $269.00K | $426.00K | $277.00K | $108.00K |
| Total Current Assets | $37.85M | $49.11M | $35.69M | $47.18M | $28.80M | $34.69M | $44.33M | $52.00M | $57.94M | $44.10M | $50.94M | $57.40M | $62.85M | $67.07M | $59.35M | $22.88M | $21.42M | $28.17M | $22.14M | $28.21M |
| Property Plant Equipment Net | $1.65M | $1.80M | $1.72M | $1.89M | $2.02M | $2.23M | $2.36M | $2.50M | $2.02M | $2.03M | $2.13M | $2.28M | $2.35M | $2.55M | $2.54M | $2.70M | $2.88M | $3.07M | $3.26M | $3.47M |
| Goodwill | $- | $- | $- | $- | $- | $21.99M | $21.94M | $- | $21.69M | $21.68M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $13.69M | $14.19M | $14.85M | $22.03M | $22.01K | $21.96K | $21.89M | $21.72K | $21.70K | $21.70M | $21.70M | $21.70M | $21.71M | $21.71M | $21.71M | $21.73M | $21.75M | $21.77M | $21.89M |
| Goodwill and Intangible Assets | $13.25M | $13.69M | $14.19M | $14.85M | $22.03M | $22.01M | $21.96M | $21.89M | $21.72M | $21.70M | $21.70M | $21.70M | $21.70M | $21.71M | $21.71M | $21.71M | $21.73M | $21.75M | $21.77M | $21.89M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Assets | $14.89M | $15.49M | $15.91M | $16.74M | $24.05M | $24.24M | $24.32M | $24.38M | $23.73M | $23.73M | $23.83M | $23.99M | $24.06M | $24.26M | $24.25M | $24.41M | $24.62M | $24.82M | $25.03M | $25.36M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $52.74M | $64.60M | $51.60M | $63.92M | $52.85M | $58.94M | $68.65M | $76.38M | $81.67M | $67.84M | $74.77M | $81.39M | $86.91M | $91.33M | $83.60M | $47.29M | $46.04M | $52.99M | $47.17M | $53.57M |
| Account Payables | $4.63M | $6.27M | $8.26M | $10.87M | $8.44M | $6.73M | $7.14M | $6.97M | $5.83M | $7.34M | $5.78M | $5.57M | $5.44M | $5.32M | $5.76M | $5.92M | $5.93M | $7.40M | $7.49M | $7.79M |
| Short Term Debt | $10.34M | $11.16M | $4.15M | $3.67M | $3.60M | $3.45M | $2.94M | $2.40M | $953.00K | $1.16M | $2.05M | $2.92M | $3.74M | $3.53M | $3.36M | $3.28M | $3.17M | $3.07M | $2.97M | $2.89M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $2.25M | $5.48M | $9.03M | $12.96M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.27M |
| Other Current Liabilities | $7.74M | $7.62M | $9.94M | $3.35M | $2.68M | $2.26M | $1.97M | $1.32M | $1.35M | $1.13M | $1.26M | $1.23M | $1.13M | $1.07M | $1.10M | $1.44M | $1.37M | $1.26M | $1.30M | $1.28M |
| Total Current Liabilities | $24.96M | $30.52M | $31.37M | $30.85M | $14.72M | $12.45M | $12.04M | $10.68M | $8.13M | $9.63M | $9.10M | $9.72M | $10.31M | $9.92M | $10.22M | $10.64M | $10.48M | $11.72M | $11.77M | $11.97M |
| Long Term Debt | $19.27M | $20.10M | $7.17M | $7.92M | $9.71M | $10.08M | $9.94M | $10.36M | $9.86M | $1.45M | $1.66M | $1.73M | $1.68M | $2.71M | $3.49M | $4.40M | $5.16M | $5.96M | $6.71M | $7.56M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $11.93M | $15.29M | $15.35M | $7.55M | $4.51M | $8.16M | $186.00K | $604.00K | $1.86M | $4.01M | $4.81M | $5.25M | $10.22M | $5.60M | $6.08M | $182.00K | $658.00K |
| Total Non-Current Liabilities | $19.27M | $20.10M | $7.17M | $19.85M | $25.00M | $25.44M | $17.49M | $14.86M | $18.02M | $1.64M | $2.26M | $3.58M | $5.69M | $7.52M | $8.74M | $14.62M | $10.76M | $12.04M | $6.90M | $8.22M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $44.24M | $50.62M | $38.54M | $50.70M | $39.72M | $37.88M | $29.53M | $25.54M | $26.15M | $11.27M | $11.36M | $13.30M | $16.00M | $17.44M | $18.95M | $25.26M | $21.23M | $23.76M | $18.66M | $20.19M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $34.43M | $34.41M | $31.36M | $31.36M | $28.33M | $27.10M | $27.10M | $27.10M | $27.10M | $21.16M | $21.07M | $21.07M | $20.87M | $20.50M | $18.73M | $9.87M | $8.28M | $8.28M | $4.91M | $4.69M |
| Retained Earnings | $-396.64M | $-390.82M | $-391.30M | $-390.61M | $-376.72M | $-360.70M | $-342.15M | $-329.99M | $-324.26M | $-317.41M | $-309.97M | $-305.04M | $-300.74M | $-295.02M | $-288.18M | $-277.99M | $-266.00M | $-261.38M | $-254.61M | $-247.97M |
| Accumulated Other Comprehensive Income Loss | $16.30M | $17.96M | $16.12M | $16.99M | $14.65M | $14.20M | $13.72M | $13.35M | $12.44M | $12.18M | $11.90M | $11.74M | $11.74M | $11.56M | $11.20M | $10.91M | $11.42M | $11.22M | $11.07M | $10.72M |
| Other Total Stockholders Equity | $354.41M | $352.43M | $355.48M | $355.48M | $345.46M | $339.05M | $339.04M | $338.98M | $338.84M | $339.67M | $339.44M | $339.35M | $338.05M | $335.89M | $321.92M | $279.24M | $271.11M | $271.11M | $267.14M | $265.94M |
| Total Stockholders Equity | $8.51M | $13.98M | $13.06M | $13.22M | $13.13M | $21.05M | $39.11M | $50.84M | $55.52M | $56.57M | $63.41M | $68.09M | $70.90M | $73.89M | $64.65M | $22.03M | $24.81M | $29.23M | $28.51M | $33.38M |
| Total Equity | $8.51M | $13.98M | $13.06M | $13.22M | $13.13M | $21.05M | $39.11M | $50.84M | $55.52M | $56.57M | $63.41M | $68.09M | $70.90M | $73.89M | $64.65M | $22.03M | $24.81M | $29.23M | $28.51M | $33.38M |
| Total Liabilities and Stockholders Equity | $52.74M | $64.60M | $51.60M | $63.92M | $52.85M | $58.94M | $68.65M | $76.38M | $81.67M | $67.84M | $74.77M | $81.39M | $86.91M | $91.33M | $83.60M | $47.29M | $46.04M | $52.99M | $47.17M | $53.57M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $52.74M | $64.60M | $51.60M | $63.92M | $52.85M | $58.94M | $68.65M | $76.38M | $81.67M | $67.84M | $74.77M | $81.39M | $86.91M | $91.33M | $83.60M | $47.29M | $46.04M | $52.99M | $47.17M | $53.57M |
| Total Investments | $20.34M | $30.44M | $22.18M | $38.74M | $18.24M | $22.71M | $34.22M | $40.49M | $44.16M | $29.15M | $39.14M | $44.15M | $48.13M | $48.08M | $42.04M | $5.76M | $14.28M | $21.78M | $16.11M | $22.19M |
| Total Debt | $29.61M | $31.25M | $11.31M | $11.59M | $13.31M | $13.54M | $12.88M | $12.32M | $10.81M | $2.61M | $3.71M | $4.65M | $5.42M | $6.24M | $6.85M | $7.68M | $8.32M | $9.03M | $9.69M | $10.46M |
| Net Debt | $20.78M | $21.63M | $5.32M | $7.34M | $5.59M | $3.43M | $3.81M | $1.74M | $-2.29M | $-11.39M | $-7.74M | $-8.34M | $-8.65M | $-11.25M | $-9.20M | $-9.15M | $1.77M | $3.50M | $4.62M | $5.16M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-60.61M | $-24.95M | $-27.05M | $-30.02M | $-25.45M |
| Depreciation and Amortization | $1.38M | $654.00K | $703.00K | $934.00K | $940.00K |
| Deferred Income Tax | $-2.85M | $- | $1.78M | $5.66M | $-4.17M |
| Stock Based Compensation | $2.32M | $2.25M | $1.50M | $1.27M | $1.76M |
| Change in Working Capital | $15.20M | $1.24M | $-540.00K | $-1.29M | $4.32M |
| Accounts Receivables | $-1.32M | $-650.00K | $24.00K | $428.00K | $1.11M |
| Inventory | $-1.95M | $650.00K | $-24.00K | $-428.00K | $-1.11M |
| Accounts Payables | $5.51M | $1.89M | $-564.00K | $-1.72M | $3.22M |
| Other Working Capital | $12.96M | $-650.00K | $24.00K | $428.00K | $1.11M |
| Other Non Cash Items | $21.95M | $-5.43M | $39.00K | $242.00K | $-72.00K |
| Net Cash Provided by Operating Activities | $-22.61M | $-26.24M | $-23.57M | $-23.21M | $-22.67M |
| Investments in Property Plant and Equipment | $-297.00K | $-316.00K | $-97.00K | $- | $-73.00K |
| Acquisitions Net | $-1.56M | $-4.14K | $38.13K | $- | $6.00K |
| Purchases of Investments | $-47.59M | $-44.00M | $-78.00M | $-33.50M | $-43.55M |
| Sales Maturities of Investments | $49.33M | $48.32M | $39.87M | $50.17M | $48.88M |
| Other Investing Activities | $1.56M | $4.14K | $-38.13K | $16.67M | $-6.00K |
| Net Cash Used for Investing Activities | $1.44M | $4.01M | $-38.22M | $16.67M | $5.26M |
| Debt Repayment | $-1.99M | $6.07M | $-3.57M | $-3.36M | $-1.10M |
| Common Stock Issued | $14.09M | $14.36M | $50.41M | $19.25M | $20.30M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.96M | $5.00K | $10.91M | $1.98M | $1.00K |
| Net Cash Used Provided by Financing Activities | $15.06M | $20.44M | $57.75M | $17.87M | $19.19M |
| Effect of Forex Changes on Cash | $-224.00K | $-607.00K | $207.00K | $206.00K | $108.00K |
| Net Change in Cash | $-6.33M | $-2.40M | $-3.84M | $11.53M | $1.89M |
| Cash at End of Period | $4.25M | $10.59M | $12.99M | $16.83M | $5.30M |
| Cash at Beginning of Period | $10.59M | $12.99M | $16.83M | $5.30M | $3.40M |
| Operating Cash Flow | $-22.61M | $-26.24M | $-23.57M | $-23.21M | $-22.67M |
| Capital Expenditure | $-297.00K | $-316.00K | $-97.00K | $- | $-73.00K |
| Free Cash Flow | $-22.91M | $-26.56M | $-23.67M | $-23.21M | $-22.74M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-5.82M | $484.00K | $-696.00K | $-13.88M | $-16.02M | $-18.55M | $-12.16M | $-5.73M | $-6.85M | $-7.44M | $-4.93M | $-4.30M | $-5.72M | $-6.84M | $-10.19M | $-11.99M | $-4.62M | $-6.77M | $-6.64M | $-9.87M |
| Depreciation and Amortization | $840.00K | $476.00K | $897.00K | $706.00K | $221.00K | $198.00K | $259.00K | $187.00K | $153.00K | $141.00K | $173.00K | $174.00K | $167.00K | $180.00K | $182.00K | $197.00K | $204.00K | $212.00K | $321.00K | $273.00K |
| Deferred Income Tax | $- | $- | $- | $-592.00K | $3.15M | $7.97M | $- | $- | $- | $- | $- | $- | $-767.00K | $158.00K | $4.73M | $5.77M | $-471.00K | $849.00K | $-493.00K | $-110.00K |
| Stock Based Compensation | $319.00K | $437.00K | $533.00K | $929.00K | $472.00K | $485.00K | $435.00K | $1.04M | $614.00K | $330.00K | $256.00K | $391.00K | $272.00K | $361.00K | $471.00K | $154.00K | $196.00K | $259.00K | $663.00K | $589.00K |
| Change in Working Capital | $-3.43M | $-7.20M | $-10.77M | $14.71M | $1.17M | $-948.00K | $273.00K | $1.26M | $-1.01M | $816.00K | $172.00K | $597.00K | $1.04M | $-703.00K | $-1.48M | $354.00K | $-1.08M | $-44.00K | $-520.00K | $3.64M |
| Accounts Receivables | $-432.00K | $-428.00K | $-2.47M | $-751.00K | $392.00K | $-837.00K | $-121.00K | $-239.00K | $277.00K | $-606.00K | $-82.00K | $372.00K | $864.00K | $-236.00K | $-976.00K | $- | $- | $- | $- | $- |
| Inventory | $90.00K | $-745.00K | $-936.00K | $-601.00K | $-1.35M | $- | $121.00K | $239.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $-2.12M | $-3.51M | $3.10M | $2.13M | $-111.00K | $394.00K | $1.89M | $-1.29M | $1.42M | $254.00K | $-564.00K | $180.00K | $-467.00K | $-502.00K | $-1.72M | $- | $- | $- | $3.22M |
| Other Working Capital | $-3.09M | $-3.91M | $-3.93M | $12.96M | $1 | $-1 | $-121.00K | $-625.00K | $-1 | $1 | $-82.00K | $1.16M | $864.00K | $-236.00K | $-976.00K | $2.07M | $271.00K | $92.00K | $-238.00K | $421.00K |
| Other Non Cash Items | $-1.73M | $-5.52M | $447.00K | $3.13M | $1.11M | $1.15M | $3.18M | $-2.45M | $-1.59M | $-133.00K | $-1.26M | $-2.36M | $-13.00K | $18.00K | $55.00K | $81.00K | $296.00K | $-71.00K | $-64.00K | $47.00K |
| Net Cash Provided by Operating Activities | $-9.82M | $-11.33M | $-14.11M | $4.99M | $-9.90M | $-9.68M | $-8.02M | $-5.68M | $-8.68M | $-6.29M | $-5.59M | $-5.50M | $-5.01M | $-6.83M | $-6.23M | $-5.43M | $-5.47M | $-5.57M | $-6.74M | $-5.43M |
| Investments in Property Plant and Equipment | $- | $-27.00K | $-32.00K | $-18.00K | $-27.00K | $-123.00K | $-129.00K | $-228.00K | $-26.00K | $-44.00K | $-18.00K | $-62.00K | $3.00K | $-19.00K | $-19.00K | $1.00K | $- | $-1.00K | $- | $-19.00K |
| Acquisitions Net | $- | $- | $- | $20.38M | $26.00K | $56.00K | $-6.67K | $-3.92K | $14.92K | $-10.07K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $6.00K |
| Purchases of Investments | $-5.79M | $-20.56M | $- | $-33.71M | $-7.88M | $-506.00K | $-5.50M | $-8.00M | $-27.00M | $-2.00M | $-7.00M | $-8.00M | $-12.00M | $-16.00M | $-42.00M | $-5.00M | $-4.75M | $-17.75M | $-6.00M | $-9.03M |
| Sales Maturities of Investments | $15.97M | $11.94M | $16.72M | $13.33M | $12.00M | $11.73M | $12.27M | $12.09M | $12.09M | $12.07M | $12.07M | $12.06M | $12.04M | $10.02M | $5.76M | $13.54M | $12.29M | $12.14M | $12.19M | $12.24M |
| Other Investing Activities | $- | $-1 | $16.72M | $-20.38M | $-26.00K | $-56.00K | $6.67K | $3.92K | $-14.92K | $10.07K | $5.07M | $4.09M | $2.00K | $-5.98M | $-36.24M | $8.54M | $7.54M | $-5.61M | $6.19M | $-6.00K |
| Net Cash Used for Investing Activities | $10.18M | $-8.64M | $16.69M | $-20.39M | $4.10M | $11.10M | $6.64M | $3.86M | $-14.94M | $10.03M | $5.05M | $4.00M | $40.00K | $-6.00M | $-36.26M | $8.54M | $7.54M | $-5.61M | $6.19M | $3.19M |
| Debt Repayment | $-1.04M | $18.31M | $-894.00K | $-863.00K | $-942.00K | $-134.00K | $-49.00K | $-650.00K | $8.62M | $-957.00K | $-943.00K | $-925.00K | $-877.00K | $-907.00K | $-863.00K | $-857.00K | $-1.05M | $-729.00K | $-723.00K | $-869.00K |
| Common Stock Issued | $-207.00K | $5.56M | $- | $12.19M | $1.90M | $- | $- | $-14.36M | $14.09M | $266.00K | $- | $1.10M | $2.45M | $4.09M | $42.77M | $7.80M | $- | $12.31M | $1.10M | $3.46M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $27.00K | $5.57M | $- | $410.00K | $2.54M | $- | $- | $3.00K | $- | $2.00K | $- | $- | $- | $10.91M | $5.00K | $- | $- | $1.00K | $7.00K | $- |
| Net Cash Used Provided by Financing Activities | $-1.22M | $23.88M | $-894.00K | $11.74M | $3.50M | $-134.00K | $-49.00K | $-647.00K | $22.72M | $-689.00K | $-943.00K | $174.00K | $1.57M | $14.09M | $41.91M | $6.95M | $-1.05M | $11.58M | $387.00K | $2.59M |
| Effect of Forex Changes on Cash | $81.00K | $-272.00K | $51.00K | $192.00K | $-72.00K | $-246.00K | $-98.00K | $-50.00K | $5.00K | $-499.00K | $-63.00K | $244.00K | $-9.00K | $173.00K | $-201.00K | $221.00K | $6.00K | $44.00K | $-65.00K | $59.00K |
| Net Change in Cash | $-787.00K | $3.63M | $1.74M | $-3.47M | $-2.38M | $1.04M | $-1.52M | $-2.52M | $-895.00K | $2.55M | $-1.54M | $-1.09M | $-3.41M | $1.44M | $-784.00K | $10.28M | $1.03M | $451.00K | $-225.00K | $412.00K |
| Cash at End of Period | $8.84M | $9.62M | $5.99M | $4.25M | $7.73M | $10.10M | $9.07M | $10.59M | $13.11M | $14.00M | $11.45M | $12.99M | $14.08M | $17.48M | $16.05M | $16.83M | $6.55M | $5.52M | $5.07M | $5.30M |
| Cash at Beginning of Period | $9.62M | $5.99M | $4.25M | $7.73M | $10.10M | $9.07M | $10.59M | $13.11M | $14.00M | $11.45M | $12.99M | $14.08M | $17.48M | $16.05M | $16.83M | $6.55M | $5.52M | $5.07M | $5.30M | $4.88M |
| Operating Cash Flow | $-9.82M | $-11.33M | $-14.11M | $4.99M | $-9.90M | $-9.68M | $-8.02M | $-5.68M | $-8.68M | $-6.29M | $-5.59M | $-5.50M | $-5.01M | $-6.83M | $-6.23M | $-5.43M | $-5.47M | $-5.57M | $-6.74M | $-5.43M |
| Capital Expenditure | $- | $-27.00K | $-32.00K | $-18.00K | $-27.00K | $-123.00K | $-129.00K | $-228.00K | $-26.00K | $-44.00K | $-18.00K | $-62.00K | $3.00K | $-19.00K | $-19.00K | $1.00K | $- | $-1.00K | $- | $-19.00K |
| Free Cash Flow | $-9.82M | $-11.36M | $-14.14M | $4.97M | $-9.93M | $-9.80M | $-8.14M | $-5.91M | $-8.71M | $-6.33M | $-5.60M | $-5.57M | $-5.01M | $-6.85M | $-6.25M | $-5.43M | $-5.47M | $-5.57M | $-6.74M | $-5.45M |
BioLineRx Stock Forecast
Analyst ratings, price targets, and earnings estimates for BLRX.
BLRX Analyst Ratings
Strong Buy
Based on 1 analysts in the past 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
| Date | Analyst | Firm | Price Target | Price When Posted | Upside |
|---|
BioLineRx Dividends
Explore BioLineRx's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Biotechnology
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
Ardelyx, Inc.
ARDX
|
$1.29B | $5.42 | $-0.17 | $-30.47 | $6.88 |
Lexicon Pharmaceuticals, Inc.
LXRX
|
$129.05M | $0.36 | $-0.63 | $-1.18 | $1.62 |
Seres Therapeutics, Inc.
MCRB
|
$111.15M | $0.64 | $0.00 | $949.54 | $9.37 |
ImmunityBio, Inc.
IBRX
|
$2.47B | $2.90 | $-0.59 | $-4.32 | $-3.66 |
X4 Pharmaceuticals, Inc.
XFOR
|
$53.99M | $0.32 | $-0.57 | $-1.47 | $2.92 |
Mereo BioPharma Group plc
MREO
|
$77.37M | $2.50 | $-0.04 | $-10.34 | $6.03 |
Inozyme Pharma, Inc.
INZY
|
$64.22M | $1.00 | $-1.62 | $-1.71 | $3.01 |
Terns Pharmaceuticals, Inc.
TERN
|
$293.04M | $3.45 | $-1.27 | $-5.13 | $1.81 |
Leap Therapeutics, Inc.
LPTX
|
$14.98M | $0.39 | $-3.98 | $-1.04 | $1.41 |
Verrica Pharmaceuticals Inc.
VRCA
|
$53.53M | $0.59 | $-1.48 | $-0.47 | $-3.68 |
Verona Pharma plc
VRNA
|
$5.53B | $65.36 | $-0.27 | $-21.84 | $18.51 |
Galera Therapeutics, Inc.
GRTX
|
$2.72M | $0.04 | $-1.33 | $-0.11 | $-0.05 |
Arcutis Biotherapeutics, Inc.
ARQT
|
$1.76B | $14.81 | $-1.16 | $-12.03 | $10.70 |
Protalix BioTherapeutics, Inc.
PLX
|
$159.78M | $2.17 | $0.12 | $14.46 | $3.58 |
Cidara Therapeutics, Inc.
CDTX
|
$244.92M | $22.36 | $-26.75 | $-1.01 | $1.05 |
Fortress Biotech, Inc.
FBIO
|
$44.72M | $1.62 | $-7.48 | $-0.40 | $1.08 |
Mustang Bio, Inc.
MBIO
|
$3.86M | $1.40 | $-6.00 | $-11.25 | $4721.76 |
Achilles Therapeutics plc
ACHL
|
$58.36M | $1.42 | $-1.74 | $-0.51 | $0.25 |
Aptose Biosciences Inc.
APTO
|
$8.10M | $3.78 | $-7.58 | $-10.05 | $-177.43 |
Fortress Biotech, Inc.
FBIOP
|
$47.76M | $6.50 | $-7.48 | $-0.40 | $1.08 |
Related Metrics
Explore detailed financial metrics and analysis for BLRX.